Literature DB >> 33236440

Defining the clinical phenotype of COVID-19 in children.

Vania Giacomet1, Marta Stracuzzi1, Laura Paradiso2, Maria Elisabetta Di Cosimo1, Valeria Rubinacci1, GianVincenzo Zuccotti1,2.   

Abstract

On January 7, 2020, a novel coronavirus (SARS-CoV-2) was identified as the causative agent of a cluster of pneumonia of unknown origin detected in Wuhan City by Chinese authorities. Since SARS-CoV-2 discovery, the corresponding disease (COVID-19) has rapidly expanded throughout the globe, making as a consequence the World Health Organization (WHO) declaring a pandemic. As of May 19, 2020, over 4.806.299 cases of COVID-19 had been confirmed worldwide, with more than 318.599 deaths.
© 2020 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.

Entities:  

Keywords:  COVID-19; Italy; SARS-CoV-2; children

Mesh:

Year:  2020        PMID: 33236440     DOI: 10.1111/pai.13355

Source DB:  PubMed          Journal:  Pediatr Allergy Immunol        ISSN: 0905-6157            Impact factor:   6.377


  3 in total

1.  Risk factors for bronchiolitis and asthma, and COVID-19 symptoms in young children.

Authors:  Philippe Eigenmann
Journal:  Pediatr Allergy Immunol       Date:  2021-02       Impact factor: 6.377

2.  An active learning-based approach for screening scholarly articles about the origins of SARS-CoV-2.

Authors:  Xin An; Mengmeng Zhang; Shuo Xu
Journal:  PLoS One       Date:  2022-09-16       Impact factor: 3.752

3.  Immune cell residency in the nasal mucosa may partially explain respiratory disease severity across the age range.

Authors:  Konner Winkley; Dithi Banerjee; Todd Bradley; Boryana Koseva; Warren A Cheung; Rangaraj Selvarangan; Tomi Pastinen; Elin Grundberg
Journal:  Sci Rep       Date:  2021-08-05       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.